Lifeward Ltd. 2026: Revenue $6.62M, Net income ($11.52M), EPS ($4.12) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Lifeward Ltd. reported Q2 2026 results with revenue up 15.7% YoY to $6.62M, driven by higher AlterG shipments and ReWalk sales in Europe. However, the company posted a net loss of ($11.52M) and diluted EPS of ($4.12), compared to a prior-year net loss of ($6.56M). Operational improvements included resolving AlterG supply constraints and launching ReWalk 7. The company also noted progress in reimbursement and market access, including CMS/Medicare recognition.
Lifeward Ltd. reported results for the 2026 quarter with revenue up 15.7% year-over-year to $6.62M while the company recorded a net loss of ($11.52M) and diluted loss per share of ($4.12), compared with a net loss of ($6.56M) and loss per share of ($7.01) in the prior-year quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $6.62M | $5.72M | 15.7% |
| Net income² | ($11.52M) | ($6.56M) | (75.5%) |
| Diluted EPS³ | ($4.12) | ($7.01) | 41.2% |
¹ Reported as “Revenues”. ² Reported as “Net loss”. ³ Reported as “Net loss per ordinary share, basic and diluted”.
Business Highlights
- Revenue growth was driven by higher AlterG shipments and stronger ReWalk sales in Europe.
- Expanded channel partnerships, including an exclusive CorLife workers’ comp distributor and a Verita Neuro international distributor, to broaden access.
- Product momentum included the launch of next‑gen ReWalk 7 (510k cleared March 2025) and progress integrating ORMD‑0801 and Skelable upper‑body technologies.
- Operational recovery: AlterG supply constraints from Q1 were resolved, producing a meaningful Q2 recovery and improved commercial adoption.
- Continued reimbursement and market-access gains, including CMS/Medicare progress with K1007 fee schedule recognition and a favorable ALJ ruling supporting Medicare coverage.
Original SEC Filing: Lifeward Ltd. [ LFWD ] - 10-Q - Aug. 14, 2026